Structure (Olanzapine Odt Figure 1)
Olanzapine Tablet, Orally Disintegrating
Product Images NDC 69452-563
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Olanzapine (NDC 69452-563). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Label1 (Olanzapine Odt Figure 2)
Label2 (Olanzapine Odt Figure 3)
Label3 (Olanzapine Odt Figure 4)
This is a description of Olanzapine Orally Disintegrating Tablets, USP with NDC 60452563-13. Each orally disintegrating tablet contains 15 mg of USP. The package is child-resistant and should be stored at controlled room temperature. It is advised to keep this and all drugs out of reach of children. Distributed by Bionpharma in Princeton, NJ.*
Label4 (Olanzapine Odt Figure 5)
This text provides important information about a medication containing 20 mg olanzapine USP in orally disintegrating tablets. It includes details for storage, dosage, and precautions for phenylketonurics due to phenylalanine content. The text also mentions dispensing instructions and emphasizes keeping the medication out of reach of children. Additionally, it lists the manufacturer as Bionpharma Inc. and indicates that the product is distributed in Princeton, NJ.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
